Abstract: The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.

Abstract: A method for vehicle eye tracking is described. The method includes capturing sensor data based on eye tracking of a vehicle operator. The method also includes identifying sensor data associated with an external environment of a vehicle within the captured sensor data. The method further includes filtering out a sensor data associated with the external environment from the captured sensor data to provide an internal vehicle sensor data. The method also includes controlling a vehicle interface based on the internal vehicle sensor data.

Abstract: A method for a vehicle safety is described. The method includes determining a current steering angle at which a vehicle is traveling. The method also includes displaying the current steering angle relative to a steering angle scale. The method further includes guiding an operator of the vehicle through feedback provided through a steering wheel of the vehicle while displaying the current steering angle relative to the steering angle scale.

Abstract: The present invention relates to a biological and chemical composite blockage removing agent and preparation process and use thereof, and mainly solves the problems that the existing blockage removing agents have poor blockage removal effect on organic blockages, cause damage to formations and oil-wells, produce serious environmental pollution, and corrode the equipment, pipelines, and the like. The problems can be well solved by using a technical solution of a biological and chemical composite blockage removing agent, which contains the following components in parts by mass: A. 10-50 parts of a biosurfactant; B. 5-20 parts of a chemical surfactant; wherein the chemical surfactant is an anionic-nonionic surfactant, and said technical solution can be used in the industrial production for removing the blockage in the oilfield, and reducing the injection pressure and increasing the injection.

Abstract: The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.

Abstract: The present disclosure generally relates to apparatuses, systems, and methods for separating a target species (e.g., CO2) from a gas mixture (e.g., gas stream) via an electrochemical process.

Abstract: Organism monitoring systems and devices and associated monitoring methods are described. According to one aspect, an organism monitoring device configured to be associated with an organism to be monitored includes a housing, a battery coupled with the housing, wherein the battery is configured to store electrical energy, a transmitter coupled with the housing and the battery, wherein the transmitter is configured to emit a wireless signal externally of the organism monitoring device and the organism being monitored, sensor circuitry coupled with the housing and the battery, wherein the sensor circuitry is configured to monitor an environment of the organism monitoring device, and control circuitry coupled with the housing, the sensor circuitry and the battery, and wherein the control circuitry is configured to adjust an operation of the organism monitoring device as a result of monitoring of the environment of the organism monitoring device by the sensor circuitry.

Abstract: Systems, articles, and methods directed to electrochemical systems (e.g., batteries) and the electrochemical reduction of halogenated compounds are generally described. In certain embodiments, the halogenated compound comprises at least one sulfur pentahalide (e.g., pentafluoride) group associated with a conjugated system.

Abstract: The present invention relates to compositions and methods for diagnosing and treating colorectal cancer.

Abstract: An object recognition determination produced by a perception system from data received from a ranging sensor system can be verified. A certificate can be produced that includes data for points of readings from the ranging sensor system. The points can have been segmented, by the perception system, into point sets that correspond to objects in an environment of a cyber-physical system. The certificate can also include lists of pairs of points in a point set and a velocity of the point set. A test of information in the certificate can be performed. Based on a result of the test: a rectification can be made to the perception system or the ranging sensor system or a communication can be transmitted to a control signal production module configured to produce, in response to the communication, a control signal to be transmitted to an actuator system configured to control the cyber-physical system.

Abstract: A mass spectrometry method includes detecting, in a first mass spectrometry of a sample containing a glycan having a plurality of sialic acids each modified differently, a plurality of oxonium ions derived from each of the plurality of sialic acids, and calculating relative values of intensities of the plurality of oxonium ions based on data obtained by the detection.

Abstract: Provided are a method and device for identifying an individual appliance through analysis of a harmonic component of a power signal. An operating appliance identification method includes collecting a mixed load signal from a home power distribution network, generating a first candidate appliance list by selecting first candidate appliances among individual appliances registered in an individual appliance harmonic analysis information table based on a ratio of a harmonic component value included in the mixed load signal, generating a second candidate appliance list including second candidate appliances by filtering the first candidate appliances based on a magnitude of the harmonic component value included in the mixed load signal, and identifying an operating appliance among a plurality of appliances connected to the home power distribution network by using the second candidate appliance list.

Abstract: Systems, articles, and methods directed to electrochemical systems (e.g., batteries) and the electrochemical reduction of halogenated compounds are generally described. In certain embodiments, the halogenated compound comprises a haloalkane associated with a conjugated system via at least one alkene linker or alkyne linker.

Abstract: A controller, a system including such a controller, and a method for controlling discharging of a plurality of battery packs are provided. The controller includes one or more processor and at least one tangible, non-transitory machine readable medium encoded with one or more programs configured to perform steps to minimize a corresponding voltage gradient versus charge of each battery pack to be below a predetermined threshold, and calculate a respective discharging share of each battery pack based on the charge and the voltage in an updated curve of voltage versus charge of each battery pack and the total power demand. The controller provides signals with instructions to the plurality of battery packs and/or the one or more power converters for discharging power from the plurality of battery packs based on the respective discharging share of each battery pack and/or keeping a certain battery pack idle.

Abstract: A compound represented by Formula (I), a pharmaceutically acceptable salt or ester, hydrate, solvate or crystalline form thereof is provided: The compound represented by Formula (I) is a ?-amino acid derivative, and in Formula (I) X is a single bond or O; Y is NH or C?O; Z is C?O, C?S, NH, W is C or N; A is a single bond, O, OH, OCH2, a heterocycle or N3; R1 is H or F; R2 is H, F, OH, CF3, CH2OH, CHO or R3 is H; n is 0 or 1; and m is 0 or 1.

Abstract: A method includes fitting a ML trained model to data features, the fitting generates complete data feature-set outputs that are associated with a first set of accuracy values, iteratively fitting, after an iterative removal of each data feature from the data feature-set, the ML trained model to subsets of the plurality of data features to determine respective reduced feature-set outputs, each subset lacks a different data feature of the plurality of data features, determining one or more of the reduced feature-set outputs as corresponding to a second set of accuracy values, designating the iteratively removed data features as accuracy-modifying data features, generating a first linear model, generating a second linear model based on one of the accuracy-modifying data features having a weight that is highest relative to respective different weights of the remaining ones of the accuracy-modifying data features, and identifying the second linear model as a generative model.

Abstract: An image encoding/decoding method and apparatus are provided. An image decoding method performed by an image decoding apparatus of the present invention may comprise decoding an indicator indicating whether or not partition information of a current block is derived from partition information of a corresponding block of the current block, obtaining the partition information of the current block based on the decoded indicator, and partitioning the current block based on the obtained partition information.

Abstract: Disclosed herein are methods for reversing hepatic steatosis by providing a consumable composition. Some embodiments provided include, for example, administering a compound of Formula (I) or compound of Formula (II). Some embodiments provide the composition is formulated as a dietary supplement, food ingredient or additive, a medical food, nutraceutical or pharmaceutical composition.

Abstract: The present disclosure provides improved genome editing compositions and methods for editing a human Wiskott-Aldrich syndrome gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of WAS, including but not limited to, an immune system disorder, thrombocytopenia, eczema, X-linked thrombocytopenia (XLT), or X-linked neutropenia (XLN).

Abstract: An inkjet ink is provided. The inkjet ink includes a modified high-performance engineering plastic, a polar solvent, and a wetting agent. Additionally, a 3D printing method and a 3D printing object are provided. The modified high-performance engineering plastic includes modified polyphenylene sulfide, modified polyether-ether-ketone, modified polyether sulfone, modified polyphenylsulfone, or modified polysulfone.